This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

XmAb (Alexion)

Alexion Pharmaceuticals, Inc.

Drug Names(s): XmAb (Alexion)

Description: XmAb (Alexion) is a proprietary antibody using Xencor's Xtend Fc Domain technology with an undisclosed mechanism of action.

Deal Structure: Xencor and Alexion
Xencor entered into an option and license agreement with Alexion in January 2013.

Under the terms of the agreement, Xencor granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use of the Xtend technology to evaluate and advance compounds against six different target programs during a five-year research term under the agreement, up to completion of the first multi-dose human clinical trial for each target compound. Alexion may extend the research term for an additional three years upon written notice to the Company and payment of an extension fee of $2.0 million. Alexion is responsible for conducting all research and development activities under the agreement at its own expense.

In addition, Xencor granted to Alexion an exclusive option, on a target-by-target basis, to obtain an exclusive commercial, worldwide, royalty-bearing license, with sublicensing rights, under the Xtend technology to...See full deal structure in Biomedtracker

Partners: Xencor, Inc.


XmAb (Alexion) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug